5-Amino-1MQ is a small-molecule compound that has gained attention in research for its potential role in weight management, metabolic health, and cellular energy regulation. It works primarily by targeting Nicotinamide N-methyltransferase (NNMT), an enzyme involved in metabolism, fat storage, and cellular energy balance.
How It Works
-
NNMT Inhibition: 5-Amino-1MQ inhibits NNMT, which can lead to reduced methylation of nicotinamide.
-
Boosts NAD⁺ Levels: By lowering NNMT activity, more nicotinamide is available to be converted into NAD⁺ — a crucial coenzyme for cellular energy production.
-
Metabolic Benefits: This shift may enhance fat metabolism, improve insulin sensitivity, and increase energy expenditure.
Potential Benefits (Based on early research)
-
Fat Reduction – May support weight loss by increasing fat breakdown and reducing fat cell size.
-
Improved Energy Levels – Higher NAD⁺ levels may boost mitochondrial function and overall vitality.
-
Metabolic Health – Could improve glucose regulation and insulin sensitivity.
-
Cellular Longevity – NAD⁺ support may contribute to healthier aging processes.
Usage in Research
-
Form: Typically provided as a capsule or powder for experimental purposes.
-
Common Research Dosages: Often in the range of 50–100 mg daily in studies, but human clinical data is limited.
-
Duration: Research protocols often run for 4–8 weeks.
Safety & Considerations
-
Human Trials: Limited — most evidence is from animal and cellular studies.
-
Side Effects: Rarely reported in research settings, but possible effects could include mild gastrointestinal discomfort or headaches.
-
Not FDA Approved: 5-Amino-1MQ is not an approved drug or supplement for medical use — available only for research purposes.
In summary:
5-Amino-1MQ is a promising NNMT inhibitor with potential benefits for weight loss, metabolic improvement, and cellular energy enhancement. While early research is encouraging, more human studies are needed to confirm its safety and efficacy.Buy 5-amino-1mq




Reviews
There are no reviews yet.